Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05706909 · ClinicalTrials.gov registry record
The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head
A clinical trial of Avascular Necrosis and Osteonecrosis, sponsored by The Cleveland Clinic.
- Active
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT05706909: Active study of Avascular Necrosis and Osteonecrosis, sponsored by The Cleveland Clinic.
NCT05706909 is a study of Avascular Necrosis and Osteonecrosis that is active but no longer recruiting, run by The Cleveland Clinic. The registered enrollment target is 22 participants, below the 294-participant average among 24 other Avascular Necrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05706909, a study of Avascular Necrosis and Osteonecrosis, is active but no longer recruiting, sponsored by The Cleveland Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.
Primary Outcome
Assessment of bone regeneration
Conditions Studied
Interventions
- DEVICE Genex with ABMC
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2027-07 |
What the registry record for NCT05706909 still lists
NCT05706909 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 294-participant average among 24 other Avascular Necrosis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Avascular Necrosis appearing as the primary indexed condition, and to 1 intervention - of which Genex with ABMC is the first listed.
NCT05706909 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05706909 about?
NCT05706909 is a clinical study titled "The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head". The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.
What is the current status of trial NCT05706909?
This trial is currently active not recruiting. The enrollment target is 22 participants. The study started on 2023-02-08. Estimated completion is 2027-07.
What conditions does trial NCT05706909 study?
This clinical trial studies the following conditions: Avascular Necrosis, Osteonecrosis.
What interventions are being tested in trial NCT05706909?
The interventions under investigation include: Genex with ABMC (DEVICE).
Who is sponsoring clinical trial NCT05706909?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05706909 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Avascular Necrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05706909's enrollment target sits among peer trials
22 25th of 24 the lowest of 24 other Avascular Necrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Avascular Necrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
RECRUITING · Phase 2
-
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
RECRUITING
-
Perform Humeral System Study
RECRUITING
-
A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System
ACTIVE NOT RECRUITING
-
Sickle Cell Disease (SCD) Bone Pain Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI